Abstract
ABSTRACTSafety monitoring and reporting has achieved a greater level of attention in the past 15 years. Statisticians play an important role in learning about a drug's safety profile. An ASA safety monitoring working group was established with a goal to empower the biostatistics community to play a proactive role and better enable quantification in safety monitoring. As part of its effort, this article presents a systematic review and unique perspective on the existing methodology developments, which include Bayesian and frequentist, blinded versus unblinded safety monitoring, individual versus aggregate data meta-analyses, pre-, and post-marketing methods, static versus dynamic safety reviews, and methods of visualization. These perspectives may serve as a background for future statistical work, both in methodology development and its application.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
